WuXi-backed Adagene scores $69M round led by General Atlantic to push antibodies where Bristol-Myers struggled
Back when Peter Luo founded Adagene in 2012, much of China was still focused on biosimilars and contract services as the industry struggled to bring manufacturing quality up to global standards. But the Stanford-trained scientist and battle-tested entrepreneur — together with longtime friend and WuXi founder Ge Li — saw an opportunity to begin building a platform play centered around engineering better antibodies.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.